Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: An observational study

Lancet

Volumn 357, Issue 9262, 2001, Pages 1063-1068

  Aronow, Herbert D ^a   Topol, Eric J ^a   Roe, Matthew T ^b   Houghtaling, Penny L ^a   Wolski, Katherine E ^a   Lincoff, A Michael ^a   Harrington, Robert A ^b   Califf, Robert M ^b   Ohman, E Magnus ^b   Kleiman, Neal S ^c   Keltai, Matyas ^d   Wilcox, Robert G ^e   Vahanian, Alec ^f   Armstrong, Paul W ^g   Lauer, Michael S ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d Hungarian Institute of Cardiology   (Hungary)

^e QUEEN S MEDICAL CENTRE   (United Kingdom)

^f BICHAT HOSPITAL   (France)

^g UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; EPTIFIBATIDE; HEPARIN; RECOMBINANT HIRUDIN; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR;

ACUTE DISEASE; ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HEART MUSCLE ISCHEMIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MORALITY; PRESCRIPTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0035820313     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(00)04257-4     Document Type: Article

References (33)

1. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
2. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
3. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
4. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS
5. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
6. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina)
7. 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction: Executive summary and recommendations: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction)
8. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes: The RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial
9. Vascular function in the forearm of hypercholesterolaemic patients off and on lipid-lowering medication
10. Hyperlipidemia and coronary disease: Correction of the increased thrombogenic potential with cholesterol reduction
11. Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia
12. HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia
13. Statins and C-reactive protein
14. Effect of statins on C-reactive protein in patients with coronary artery disease
15. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes
16. Design and methodology of the PURSUIT trial: Evaluating eptifibatide for acute ischemic coronary syndromes. Platelet glycoprotein IIb-IIIa in unstable angina: Receptor suppression using integrilin therapy
17. Cause of death in clinical research: Time for a reassessment?
18. Estimating causal effects from large data sets using propensity scores
19. Invited commentary: Propensity scores
20. Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation: Results from an international trial of 9461 patients
21. Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction: Results from an international trial of 41,021 patients
22. Early statin treatment following acute myocardial infarction and 1-year survival
23. Rationale and design of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study that evaluates atorvastatin in unstable angina pectoris and in non-Q-wave acute myocardial infarction
24. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors
25. Statins as a newly recognized type of immunomodulator
26. Early beta-blocker therapy for acute myocardial infarction in elderly patients
27. A comparison of observational studies and randomized, controlled trials
28. Randomized, controlled trials, observational studies, and the hierarchy of research designs
29. Use of cholesterol-lowering medications in the United States from 1991 to 1997
30. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol
31. Drug treatment of lipid disorders
32. Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics